Lv1
44 积分 2024-07-09 加入
ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer
5天前
已完结
Guideline for the management pathway and quality control of ovarian cancer diagnosis and treatment in county-level regions of China (2025 Edition)
1个月前
已关闭
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
1个月前
已完结
The first Chinese National Union of Real-world Gynaecological Oncology Research and Patient Management Platform: A retrospective study
3个月前
已完结
Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR -Mutant Lung Adenocarcinomas
5个月前
已完结
Bevacizumab, atezolizumab and acetylsalicylic acid in recurrent, platinum-resistant ovarian cancer: the EORTC 1508-GCG phase II study
5个月前
已完结
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
8个月前
已完结
Advances in the management of peritoneal malignancies
8个月前
已完结
SOCS3 inhibiting JAK-STAT pathway enhances oncolytic adenovirus efficacy by potentiating viral replication and T-cell activation
9个月前
已完结
皖公网安备34019202002308
